Abzena PLC (LON:ABZA)‘s stock had its “under review” rating reaffirmed by equities researchers at FinnCap in a research note issued to investors on Thursday.

Separately, Numis Securities Ltd reiterated a “buy” rating and set a GBX 93 ($1.20) price target on shares of Abzena PLC in a report on Tuesday, July 11th.

Shares of Abzena PLC (LON:ABZA) remained flat at GBX 34.00 during trading on Thursday. The company’s stock had a trading volume of 10,950 shares. Abzena PLC has a 12 month low of GBX 31.00 and a 12 month high of GBX 66.00. The firm’s market capitalization is GBX 46.87 million. The company has a 50 day moving average of GBX 45.41 and a 200-day moving average of GBX 41.25.

COPYRIGHT VIOLATION WARNING: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/16/abzena-plcs-abza-under-review-rating-reaffirmed-at-finncap.html.

About Abzena PLC

Abzena plc is a life sciences company. The Company provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups.

Receive News & Ratings for Abzena PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abzena PLC and related companies with MarketBeat.com's FREE daily email newsletter.